Menu
Cancer immunotherapy, also known as immuno-oncology or cell-based therapy, is an exciting and innovative approach to cancer treatment. This method leverages the natural defenses of the immune system, stimulating them to recognize, attack, and destroy cancer cells. Cancer immunotherapy is built upon a technology that enhances the ability of immune cells to battle cancer, making them more powerful and effective
The research and advancement of immunotherapy have implications far beyond cancer treatment. It is anticipated that immunotherapy may also play a pivotal role in the treatment of diseases where the immune system is involved, such as autoimmune diseases
The Hadassah Cancer Research Institute (HCRI) is focusing on cell-based therapy, employing cutting-edge technologies. We are engaged in the development of new generation immunotherapy, personalized medicine, multi-layer profiling of tumor tissues, and the advanced use of databases collected at Hadassah
Special emphasis is placed on HCRI’s collaborations with research institutes and pharmaceutical companies. Our aim is to foster the creation of innovative therapeutics, thereby enabling more effective treatment options for the benefit of cancer patients worldwide
Tumor infiltrating lymphocytes (TILs) consist of all lymphocytic cell populations that have invaded the tumor tissue. TILs have been described in a number of solid tumors, including breast cancer, and are emerging as an important biomarker in predicting the efficacy and outcome of treatment.
The development of T cell receptor (TCR) isolation technology and genetic engineering programs have enabled patients’ T cells to express TCRs recognizing multiple combinations of specific peptides and human leukocyte antigens (HLA). The resulting TCR-T cells can specifically recognize tumor-associated antigens and effectively eliminate tumor cells.
